Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer

Cancer Medicine

Volumn 1, Issue 3, 2012, Pages 318-327

  Haque, Reina ^a   Ahmed, Syed A ^a   Fisher, Alice ^a   Avila, Chantal C ^a   Shi, Jiaxiao ^a   Guo, Amy ^b   Craig Cheetham, T ^a   Schottinger, Joanne E ^a  

^a KAISER PERMANENTE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

AI; Breast cancer; Comparative effectiveness; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVOR; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION;

EID: 84894350621     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.37     Document Type: Article

References (32)

1. American Cancer Society. 2012. Cancer facts and figures 2012. Am. Cancer Soc. Available at http://www.cancer.org. Accessed 3 February 2012.
2. Hewitt, M., S. Greenfield, and E. Stoval 2006. From cancer patient to cancer survivor: lost in translation. The National Academy Press, Washington, DC.
3. Goldhirsch, A., J. H. Glick, R. D. Gelber, A. S. Coates, B. Thürlimann, and H. J. Senn, Panel members. 2005. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann. Oncol. 16:1569-1583.
4. Arora, A., and J. F. Potter 2004. Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer. J. Am. Geriatr. Soc. 52:611-616.
5. Winer, E. P., C. Hudis, H. J. Burstein, J. Bryant, R. T. Chlebowski, J. N. Ingle, et al. 2003. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J. Clin. Oncol. 21:2597-2599.
6. Winer, E. P., C. Hudis, H. J. Burstein, A. C. Wolff, K. I. Pritchard, J. N. Ingle, et al. 2005. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol. 23:619-629.
7. Mauri, D., N. Pavlidis, N. P. Polyzos, and J. P. Ioannidis 2006. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta analysis. J. Natl. Cancer Inst. 98:1285-1291.
8. Perez, E. A. 2007. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann. Oncol. 18:viii, 26-35.
9. Bhatnagar, A. 2007. The discovery and mechanism of action of letrozole. Breast Cancer Res. Treat. 105:7-17.
10. Burstein, H. J., A. A. Prestrud, J. Seidenfeld, and S. Temin 2010. American Society of Clinical Oncology Clinical Practice Guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol. 28:1-24.
11. NCCN Practice Guidelines in Oncology - v.2.2005. 2007. Invasive breast cancer, adjuvant hormonal therapy. National Comprehensive Cancer Network Web Site. Available at http://www.nccn.org. Accessed 16 February 2007.
12. Visvanathan, K., R. T. Chlebowski, P. Hurley, and S. Temin 2009. American Society of Clinical Oncology Clinical Practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J. Clin. Oncol. 27:3235-3258.
13. Owusu, C., T. L. Lash, and R. A. Silliman 2007. Effectiveness of adjuvant tamoxifen therapy among older women with early stage breast cancer. Breast J. 13:374-382.
14. BIG 1-98 Collaborative Group, H. Mouridsen, A. Giobbie-Hurder, A. Goldhirsch, B. Thürlimann, R. Paridaens, I. Smith, L. Mauriac, J. F. Forbes, K. N. Price, M. M. Regan, and R. D. Gelber, et al. 2009. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N. Engl. J. Med. 361:766-776.
15. Cuzick, J. 2005. Aromatase inhibitors for breast cancer prevention. J. Clin. Oncol. 23:1636-1643.
16. Breast International Group (BIG) 1-98 Collaborative Group, B. Thurlimann, A. Keshaviah, A. S. Coates, H. Mouridsen, L. Mauriac, J. F. Forbes, R. Paridaens, M. Castiglione-Gertsch, R. D. Gelber, M. Rabaglio, and I. Smith, et al. 2005. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353:2747-2757.
17. Goss, P. E., J. N. Ingle, S. Martino, N. J. Robert, H. B. Muss, M. J. Piccart, et al. 2003. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349:1703-1802.
18. Howell, A., J. Cuzick, M. Baum, A. Buzdar, M. Dowsett, J. F. Forbes, et al.; ATAC Trialists' Group. 2005. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62.
19. Geiger, A., S. S. Thwin, D. S. Buist, M. N. Prout, F. Wei, T. S. Field, et al. 2007. Recurrences and second primary breast cancers in older women with initial early stage disease. Cancer 109:966-974.
20. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). 1998. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451-1467.
21. Cleves, M. A., N. Sanchez, and M. Draheim 1997. Evaluation of two competing methods for calculating Charlson's comorbidity index when analyzing short-term mortality using administrative data. J. Clin. Epidemiol. 50:903-908.
22. Lash, T., and S. R. Cole 2009. Immortal person time in studies of cancer outcomes. J. Clin. Oncol. 27:e55-e56.
23. Andrade, S. E., K. H. Kahler, F. Frech, and K. A. Chan 2006. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol. Drug Saf. 15:565-574.
24. Aiello, E., D. S. Buist, E. D. Wagner, L. Tuzzio, S. M. Greene, L. E. Lamerato, et al. Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. 2008. Breast Cancer Res. Treat. 107:397-403.
25. Winer, E. P., C. Hudis, H. J. Burstein, R. T. Chlebowski, J. N. Ingle, S. B. Edge, et al. 2002. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J. Clin. Oncol. 220:3317-3327.
26. Ligibel, J. A., and E. A. Winer 2005. Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions. Breast Cancer Res. 7:255-257.
27. Hershman, D. L., T. Shao, L. H. Kushi, D. Buono, W. Y. Tsai, L. Fehrenbacher, et al. 2011. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res. Treat. 126:529-37.
28. Hershman, D. L., L. H. Kushi, T. Shao, D. Buono, W. Y. Tsai, L. Fehrenbacher, et al. 2010. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8, 769 early-stage breast cancer patients. J. Clin. Oncol. 28:4120-4128.
29. Enger, S. M., J. M. Greif, J. Polikoff, and M. Press 2004. Body weight correlates with mortality in early stage breast cancer. Arch. Surg. 139:954-960.
30. Henry, N. L., J. T. Giles, D. Ang, M. Mohan, D. Dadabhoy, J. Robarge, et al. 2008. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res. Treat. 111:365-372.
31. Winer, E. P., C. Hudis, H. J. Burstein, A. C. Wolff, K. I. Pritchard, J. N. Ingle, et al. 2004. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone-receptor-positive breast cancer: status report. J. Clin. Oncol. 23:619-629.
32. Coombes, R. C., E. Hall, L. J. Gibson, R. Paridaens, J. Jassem, T. Delozier, et al. 2004. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350:1081-1092.